Adfovir dipivoxil tablets, a new hepatitis B drug of Guangji pharmaceutical industry, will soon be approved for production

On November 8, the progress of drug registration showed that the drug handling status of acceptance No "cxhs0700445 e" was changed to "certificate preparation completed - approved document" "The variety that may be approved in the near future should be adefovir dipivoxil tablets," Guangji pharmaceutical said in an interview yesterday But at present, the company has not officially received the approval " It is understood that adefovir dipivoxil is a new antiviral drug, which has a good effect on adult chronic hepatitis B patients with compensatory liver function, especially for those who need long-term medication or have developed lamivudine resistance Hepatitis B is a kind of serious epidemic disease There are more than 100 million people living with hepatitis B virus in China It is one of the most popular and harmful diseases in China It is reported that Guangji pharmaceutical began to declare this variety in 2007, and the approved production is expected to open the door of domestic hepatitis B market for the company At present, Guangji pharmaceutical is mainly engaged in vitamin B related products At present, the common clinical liver disease refers to various types of viral hepatitis, liver cancer and drug-induced liver injury Therefore, there are antiviral drugs, interferon antiviral drugs, nucleotide antiviral drugs, immunomodulatory drugs and so on At present, the main nucleotide drugs used in clinic are lamivudine, adefovir Dipivoxil and entecavir According to the analysis of medical industry researchers, hepatitis B is a high incidence disease in China, so hepatitis B drugs have a huge market space, especially the market size and development prospects of hepatitis B vaccine can not be ignored According to a new report on China's hepatitis B market, the size of China's hepatitis B drug market is expected to expand from US $601 million in 2010 to nearly US $900 million in 2015.